StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
17
This year
1
Publishing Date
2024 - 03 - 11
1
2023 - 12 - 15
1
2023 - 12 - 08
1
2023 - 11 - 30
1
2023 - 11 - 17
1
2023 - 08 - 23
1
2023 - 08 - 05
1
2023 - 07 - 06
1
2023 - 05 - 12
1
2023 - 01 - 20
1
2022 - 12 - 20
2
2022 - 08 - 18
1
2022 - 06 - 27
1
2022 - 06 - 26
1
2022 - 06 - 23
1
2021 - 10 - 21
1
Sector
Communications
1
Health technology
17
Manufacturing
17
Tags
Acquisition
4
Advanced
5
Agreement
19
Alliances
6
America
15
Antibody
6
Application
18
Approved
5
Asco
4
Asia
7
At845
5
Authorization
5
Biotech
7
Biotech-bay
7
Bladder
12
Cancer
49
Cell
7
Children
4
China
4
Chmp
4
Collaboration
15
Companies
12
Cresemba
4
Disease
16
Drug
26
Earnings
4
Events
5
Expected
4
Fda
17
Financial
4
Genetown
5
Global
27
Grants
4
Growing
6
Growth
47
Health
4
Japan
7
Leukemia
6
License
17
Management
7
Market
113
N/a
269
Padcev
11
Pharma
13
Pharmaceutical
5
Positive
14
Reach
5
Report
24
Research
43
Results
19
Set
5
Study
14
Therapeutics
35
Therapy
23
Topline
10
Treatment
50
Trial
22
Update
6
Vaccine
7
Xtandi
6
Entities
22nd century group, inc
10
Abbott laboratories
79
Abbvie inc.
42
Acer therapeutics inc.
12
Adma biologics inc
18
Amgen inc.
23
Amneal pharmaceuticals, inc.
15
Ani pharmaceuticals, inc.
17
Apyx medical corporation
12
Aquestive therapeutics, inc.
15
Ardelyx, inc.
11
Arrival
10
Astellas pharma inc
17
Avenue therapeutics, inc.
10
Becton, dickinson and company
13
Beigene, ltd.
16
Biogen inc.
32
Biomarin pharmaceutical inc.
10
Biontech se
24
Bluebird bio, inc.
13
Boston scientific corporation
11
Brainstorm cell therapeutics inc.
14
Bristol-myers squibb company
20
Coherus biosciences, inc.
23
Eagle pharmaceuticals, inc.
11
Eli lilly and company
71
Eyenovia, inc.
13
Fortress biotech, inc.
14
Gilead sciences, inc.
21
Glaxosmithkline plc
14
Incyte corporation
23
Inhibikase therapeutics, inc.
10
Ionis pharmaceuticals, inc.
13
Jaguar health, inc.
16
Johnson & johnson
225
Medtronic plc
28
Merck & company, inc.
36
Mesoblast limited
15
Moderna, inc.
13
Novartis ag
28
Novavax, inc.
11
Novo nordisk a/s
11
Ocugen, inc.
15
Orange
63
Perrigo company
90
Pfizer, inc.
74
Reata pharmaceuticals, inc.
12
Regeneron pharmaceuticals, inc.
50
Sanofi
236
Seagen inc.
10
Soligenix, inc.
14
Sorrento therapeutics, inc.
21
T2 biosystems, inc.
14
Takeda pharmaceutical company limited
16
Teva pharmaceutical industries ltd
22
Thermo fisher scientific inc
16
Tonix pharmaceuticals holding corp.
12
Verrica pharmaceuticals inc.
13
Vertex pharmaceuticals incorporated
14
Veru inc.
14
Symbols
ALPMF
17
ALPMY
17
FNCTF
1
ISEE
1
MRK
2
PFE
4
SGEN
3
Exchanges
Nasdaq
17
Nyse
6
Crawled Date
2024 - 03 - 11
1
2023 - 12 - 15
1
2023 - 12 - 08
1
2023 - 11 - 30
1
2023 - 11 - 17
1
2023 - 08 - 23
1
2023 - 08 - 05
1
2023 - 07 - 06
1
2023 - 05 - 12
1
2023 - 01 - 20
1
2022 - 12 - 20
2
2022 - 08 - 18
1
2022 - 06 - 27
2
2022 - 06 - 24
1
2021 - 10 - 21
1
Crawled Time
00:00
2
04:00
1
04:20
1
06:00
1
07:00
2
08:00
1
12:00
3
12:20
1
13:00
1
19:00
1
22:00
3
Source
www.biospace.com
5
www.ivericbio.com
1
www.prnewswire.com
11
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Fda
entities :
Astellas pharma inc
save search
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Published:
2024-03-11
(Crawled : 13:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-12.05%
|
O:
-1.41%
H:
5.06%
C:
4.01%
cresemba
fda
drug
children
grants
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published:
2023-12-15
(Crawled : 22:00)
- prnewswire.com
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
Email alert
Add to watchlist
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
Email alert
Add to watchlist
padcev
fda
first
approved
bladder
cancer
treat
advanced
plus
FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Published:
2023-12-08
(Crawled : 22:00)
- biospace.com/
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
-6.87%
|
O:
0.68%
H:
0.0%
C:
0.0%
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-22.28%
|
O:
-2.79%
H:
0.62%
C:
0.62%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-23.82%
|
O:
-2.2%
H:
0.0%
C:
-0.27%
cresemba
fda
children
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published:
2023-11-30
(Crawled : 22:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-18.49%
|
O:
3.87%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-23.19%
|
O:
-3.37%
H:
4.51%
C:
4.51%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-16.57%
|
O:
-4.92%
H:
1.48%
C:
-0.21%
padcev
fda
license
review
bladder
cancer
treatment
application
grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published:
2023-11-17
(Crawled : 04:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-17.29%
|
O:
0.04%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-19.27%
|
O:
1.38%
H:
1.79%
C:
1.79%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-14.61%
|
O:
0.5%
H:
0.3%
C:
0.0%
xtandi
fda
approved
cancer
treatment
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published:
2023-08-23
(Crawled : 12:00)
- biospace.com/
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-38.75%
|
O:
0.59%
H:
0.46%
C:
0.46%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-31.0%
|
O:
0.68%
H:
0.11%
C:
-1.16%
xtandi
fda
review
cancer
grants
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
Published:
2023-08-05
(Crawled : 04:20)
- ivericbio.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
Email alert
Add to watchlist
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
ISEE
|
$39.95
0.38%
0.38%
0
|
Health Technology
|
Email alert
Add to watchlist
fda
approval
treatment
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
Published:
2023-07-06
(Crawled : 06:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-34.65%
|
O:
0.86%
H:
0.0%
C:
-1.01%
fda
license
review
application
grants
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
Published:
2023-05-12
(Crawled : 19:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
Email alert
Add to watchlist
fda
approved
treatment
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published:
2023-01-20
(Crawled : 07:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-37.62%
|
O:
-1.43%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-38.06%
|
O:
-0.07%
H:
1.33%
C:
1.26%
at845
treatment
fda
disease
lifted
trial
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published:
2022-12-20
(Crawled : 12:20)
- biospace.com/
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-39.15%
|
O:
1.66%
H:
1.12%
C:
0.03%
MRK
|
$125.37
0.25%
0.1%
6.1M
|
Health Technology
|
14.56%
|
O:
0.46%
H:
0.65%
C:
-0.21%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
79.22%
|
O:
0.0%
H:
4.57%
C:
4.22%
padcev
treatment
fda
cancer
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published:
2022-12-20
(Crawled : 12:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-39.15%
|
O:
1.66%
H:
1.12%
C:
0.03%
MRK
|
$125.37
0.25%
0.1%
6.1M
|
Health Technology
|
14.56%
|
O:
0.46%
H:
0.65%
C:
-0.21%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
79.22%
|
O:
0.0%
H:
4.57%
C:
4.22%
padcev
treatment
fda
license
cancer
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
Published:
2022-08-18
(Crawled : 07:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-35.18%
|
O:
2.87%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-38.02%
|
O:
-0.8%
H:
0.33%
C:
-0.8%
fda
drug
application
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published:
2022-06-27
(Crawled : 08:00)
- biospace.com/
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-42.36%
|
O:
-1.2%
H:
0.0%
C:
-0.37%
at845
fda
disease
trial
update
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published:
2022-06-26
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-42.36%
|
O:
-1.2%
H:
0.0%
C:
-0.37%
at845
fda
disease
trial
update
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Published:
2022-06-23
(Crawled : 00:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-39.1%
|
O:
0.99%
H:
0.0%
C:
-0.5%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-41.33%
|
O:
4.33%
H:
0.0%
C:
-2.44%
fda
drug
application
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
Published:
2021-10-21
(Crawled : 12:00)
- biospace.com/
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-44.51%
|
O:
-4.45%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-45.16%
|
O:
-0.12%
H:
0.53%
C:
0.06%
fda
phase 2
sensor
acquired
phase 2b
hearing loss
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.